After Apellis (APLS) announced results from the Phase 3 PEGASUS study evaluating pegcetacoplan in adults with paroxysmal nocturnal hemoglobinuria showing that egcetacoplan met the study's primary efficacy endpoint, demonstrating superiority to eculizumab, which is sold under the trade name Soliris by Alexion (ALXN), William Blair analyst Raju Prasad said the percentage of patients who suffer from extravascular hemolysis despite treatment with Soliris remains in question. Prasad, who makes no change to his Outperform rating on Alexion shares, said that while APL-2, if approved, could cause future headwinds int he PNH landscape, he thinks Alexion's complement franchise sales will continue to grow in neurology indications, including generalized myasthenia gravis and neuromyelitis optica spectrum disorder.